Guggenheim Names Celldex Its Top Biotech Pick Ahead of Fall Phase III Data
Guggenheim Securities has designated Celldex Therapeutics as its leading biotechnology selection, highlighting the commercial promise of the company’s lead candidate, barzolvolimab, in the chronic urticaria market. Analysts kept a Buy rating and a $100 price target while pointing to approaching Phase III topline readouts and additional clinical upd…